 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142...143144» |
- albumin-bound paclitaxel / Generic mfg.
Trial initiation date, IO biomarker, Metastases: Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer (clinicaltrials.gov) - Jun 24, 2013
P2, N=29, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Apr 2012 --> Aug 2012
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jun 20, 2013
P3, N=164, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (clinicaltrials.gov) - Jun 20, 2013
P2, N=100, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial: Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 (clinicaltrials.gov) - Jun 20, 2013
P1/2, N=30, Recruiting, Sponsor: Weill Medical College of Cornell University
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (clinicaltrials.gov) - Jun 18, 2013
P2, N=82, Recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Initiation date: Apr 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, BMS-754807 / BMS
Trial termination, Combination therapy, Metastases: Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=54, Terminated, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, BMS-754807 / BMS
Trial initiation date, Combination therapy, Metastases: Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=54, Terminated, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Terminated Initiation date: Nov 2007 --> Oct 2009
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, BMS-754807 / BMS
Enrollment change, Combination therapy, Metastases: Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=54, Terminated, Sponsor: Bristol-Myers Squibb
Initiation date: Nov 2007 --> Oct 2009 N=70 --> 54
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=48, Active, not recruiting, Sponsor: Emory University
N=70 --> 54 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery, Metastases: Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 16, 2013
P2, N=37, Completed, Sponsor: Medical University of South Carolina
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: ITACa: Sequential Treatment Strategy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 13, 2013
P3, N=350, Recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis (clinicaltrials.gov) - Jun 12, 2013
P2, N=73, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) (clinicaltrials.gov) - Jun 11, 2013
P2, N=52, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jun 10, 2013
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) - Jun 9, 2013
P1, N=100, Recruiting, Sponsor: James Graham Brown Cancer Center
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial: De-ESCALaTE: Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC (clinicaltrials.gov) - Jun 6, 2013
P3, N=304, Recruiting, Sponsor: University of Warwick
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, RG4733 / Roche
Trial termination, Metastases: Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 4, 2013
P1, N=60, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Jun 4, 2013
P1, N=22, Recruiting, Sponsor: Georgetown University
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Jun 3, 2013
P1, N=22, Recruiting, Sponsor: Georgetown University
Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
New P2 trial, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Jun 2, 2013
P2, N=80, Recruiting, Sponsor: Academic and Community Cancer Research United
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Nordic 8 - A Phase II Trial (clinicaltrials.gov) - Jun 2, 2013
P2, N=180, Recruiting, Sponsor: Per Pfeiffer
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: EMR 62202-832: Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - May 28, 2013
P2, N=3, Terminated, Sponsor: University of Malaya
Not yet recruiting --> Recruiting Recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - May 28, 2013
P1, N=13, Recruiting, Sponsor: University of Washington
Recruiting --> Terminated N=18 --> 13
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: EMR 62202-832: Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - May 28, 2013
P2, N=3, Terminated, Sponsor: University of Malaya
N=18 --> 13 N=20 --> 3
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (clinicaltrials.gov) - May 28, 2013
P2, N=82, Recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Na (clinicaltrials.gov) - May 22, 2013
P3, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
N=20 --> 3 N=825 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Metastases: A Phase Ib Trial of Concurrent Cetuximab (ERBITUX (clinicaltrials.gov) - May 20, 2013
P1, N=18, Recruiting, Sponsor: University of Pittsburgh
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (clinicaltrials.gov) - May 19, 2013
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: TROG 12.01: Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - May 14, 2013
P3, N=200, Not yet recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=67, Completed, Sponsor: National Cancer Institute (NCI)
N=825 --> 0 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: FUTURE: Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. (clinicaltrials.gov) - May 13, 2013
P2, N=302, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| sonolisib (PX 866) / Pfizer
Enrollment closed: Phase 1 and 2 Study of PX-866 and Cetuximab (clinicaltrials.gov) - May 9, 2013
P1/2, N=178, Active, not recruiting, Sponsor: Oncothyreon Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma (clinicaltrials.gov) - May 8, 2013
P=N/A, N=8, Terminated, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Recruiting --> Terminated; This study was terminated due slow accrual.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, vadimezan (ASA404) / Antisoma
Enrollment change, Combination therapy: ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - May 8, 2013
P1, N=0, Withdrawn, Sponsor: University of California, San Francisco
Recruiting --> Terminated; This study was terminated due slow accrual. N=24 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma (clinicaltrials.gov) - May 8, 2013
P=N/A, N=8, Terminated, Sponsor: University of Colorado, Denver
N=24 --> 0 N=15 --> 8
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Monotherapy, Metastases: SAKK 41/10: Cetuximab for Elderly Patients With mCRC (clinicaltrials.gov) - May 6, 2013
P2, N=78, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=15 --> 8 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - May 5, 2013
P2, N=180, Recruiting, Sponsor: EPS Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - May 5, 2013
P=N/A, N=100, Recruiting, Sponsor: EPS Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer (clinicaltrials.gov) - May 2, 2013
P1/2, N=17, Terminated, Sponsor: Boneca Corporation
Not yet recruiting --> Recruiting Recruiting --> Terminated; The neutron facility closed down for financial reasons.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Apr 30, 2013
P2, N=35, Recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Terminated; The neutron facility closed down for financial reasons. Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment closed: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Apr 30, 2013
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 30, 2013
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: eSCOUT: Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy (clinicaltrials.gov) - Apr 25, 2013
P2, N=47, Active, not recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - Apr 23, 2013
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting --> Active, not recruiting N=60 --> 20
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - Apr 23, 2013
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
N=60 --> 20 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date: ACCEPT: Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (clinicaltrials.gov) - Apr 22, 2013
P1/2, N=49, Recruiting, Sponsor: University of Heidelberg
Recruiting --> Active, not recruiting Initiation date: Nov 2010 --> Jun 2012
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: ACCEPT: Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (clinicaltrials.gov) - Apr 22, 2013
P1/2, N=49, Recruiting, Sponsor: University of Heidelberg
Initiation date: Nov 2010 --> Jun 2012 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: TPF-C-HIT: TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors (clinicaltrials.gov) - Apr 22, 2013
P2, N=8, Terminated, Sponsor: University of Heidelberg
Not yet recruiting --> Recruiting Recruiting --> Terminated; slow recruitment (only 8 patients recruited and treated until 12/2012)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: TPF-C-HIT: TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors (clinicaltrials.gov) - Apr 22, 2013
P2, N=8, Terminated, Sponsor: University of Heidelberg
Recruiting --> Terminated; slow recruitment (only 8 patients recruited and treated until 12/2012) N=50 --> 8
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Apr 18, 2013
P2, N=180, Recruiting, Sponsor: EPS Corporation